Gedea’s ambition is to develop the first antibiotic-free treatment that both prevents and treats bacterial vaginosis. pHyph is a vaginal tablet that has been shown to have an excellent medical effect.


pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.


Bacterial vaginosis is a recurring problem that affects women around the world.


In our most recently concluded trial, 82% of the subjects were clinically cured of bacterial vaginosis after one week.

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of 4% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.1
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.


Gedea Biotech is working to reflect the progress being made in healthcare towards a more sustainable future. We are doing this partly by developing a treatment that is safe to use and which complies with all scientific processes and regulations. The fact that pHyph is free from antibiotics also plays an important role in the future treatment of bacterial vaginosis.

Annette Säfholm
+46 (0) 708 - 91 86 81
Eva Norell
Eva Norell Marketing
+46 (0) 709 - 36 04 20
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 878775